Abbott Labs Expects to Debut Epithelial Ovarian Cancer IVD Before End of Year
Abbott Labs before the end of the year plans to debut its Architect HE4 assay, which is designed to help oncologists monitor patients with epithelial ovarian cancer, the most common form of the disease. Abbott today announced it had submitted the immunoassay for regulatory approval with FDA. The company is betting the blood-based assay will [...]
